A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its ...

Agreement grants Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet ...

Harbour BioMed, a global biopharmaceutical company, and Sichuan Kelun Biotech BioPharmaceutical have entered into a license ...

Kindeva Drug Delivery, a global CDMO, and Emervax, developer of a circular RNA-based vaccine platform (emxRNA), entered an ...

Coronado Research has appointed Jo Marshall as EVP of Data Services and Advanced Analytics.

Bora Biologics, a division of CDMO Bora Pharmaceuticals, will support DotBio, a biopharmaceutical company specializing in ...

Gabe Longoria joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations Ltd. 4basebio ...

Under the agreement, UCB gains a non-exclusive license to leverage XtalFold for the discovery and engineering of biologics.

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in 4Q24, and Genenta expects to treat six ...

GEMMA Biotherapeutics —a new therapeutics company founded by gene therapy pioneer Dr. Jim Wilson—has named May Orfali, MD, ...

Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases ...